Trump Secures Drug Price Deals
Analysis based on 7 articles · First reported Dec 19, 2025 · Last updated Dec 20, 2025
The deals are expected to lead to 'massive savings' for US patients and the United States — Medicaid program, potentially increasing access to medicines. However, companies like Pfizer anticipate price and margin compression, indicating a mixed financial impact on the pharmaceutical industry.
US President Donald Trump announced deals with nine major pharmaceutical companies, including Bristol Myers Squibb, Gilead Sciences, Merck & Co., F. Hoffmann-La Roche — Genentech, Novartis, Amgen, Boehringer Ingelheim, Sanofi, and GSK plc, to significantly cut prescription drug prices. These agreements aim to align US drug costs with those in other wealthy nations, particularly for the government's United States — Medicaid program and cash payers. Key aspects of the deals include price reductions on most drugs sold to United States — Medicaid, 'most-favored-nation' pricing for new drug launches, and direct-to-consumer sales through the upcoming TrumpRx website. In return, the companies will receive a three-year exemption from tariffs and have pledged over $150 billion in US R&D and manufacturing investments. Several companies, such as Merck & Co. and Amgen, have outlined specific price cuts for their drugs. Five other companies, including Pfizer and Eli Lilly and Company, had previously struck similar deals, while Regeneron Pharmaceuticals, Johnson & Johnson, and AbbVie are expected to announce agreements soon.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard